Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Conditions

• Multiple Myeloma

Interventions

• DRUG: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen
• DRUG: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen
• DRUG: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
• DRUG: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen
• DRUG: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen
• DRUG: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
• DRUG: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance
• DRUG: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance
• DRUG: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)

Sponsor

University of Leeds

Collaborators

• [object Object]
• [object Object]
• [object Object]